171 related articles for article (PubMed ID: 10540693)
1. Orlistat. No hurry...
Can Fam Physician; 1999 Oct; 45():2331-3, 2336-8, 2343-5 passim. PubMed ID: 10540693
[TBL] [Abstract][Full Text] [Related]
2. Orlistat: new preparation. No hurry . .
Prescrire Int; 1999 Aug; 8(42):99-104. PubMed ID: 11503834
[TBL] [Abstract][Full Text] [Related]
3. Orlistat: a second look. At best, a minor adjunct to dietary measures.
Prescrire Int; 2002 Feb; 11(57):10-2. PubMed ID: 11985367
[TBL] [Abstract][Full Text] [Related]
4. Orlistat.
Wong NN; Cheng-Lai A
Heart Dis; 2000; 2(2):174-81. PubMed ID: 11728255
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland.
Lacey LA; Wolf A; O'shea D; Erny S; Ruof J
Int J Obes (Lond); 2005 Aug; 29(8):975-82. PubMed ID: 15852050
[TBL] [Abstract][Full Text] [Related]
6. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
[TBL] [Abstract][Full Text] [Related]
7. The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome.
Svendsen M; Helgeland M; Tonstad S
J Hum Nutr Diet; 2009 Feb; 22(1):55-63. PubMed ID: 19192027
[TBL] [Abstract][Full Text] [Related]
8. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
Rössner S; Sjöström L; Noack R; Meinders AE; Noseda G
Obes Res; 2000 Jan; 8(1):49-61. PubMed ID: 10678259
[TBL] [Abstract][Full Text] [Related]
9. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
[TBL] [Abstract][Full Text] [Related]
10. Effect of orlistat on eating behavior among participants in a 3-year weight maintenance trial.
Svendsen M; Rissanen A; Richelsen B; Rössner S; Hansson F; Tonstad S
Obesity (Silver Spring); 2008 Feb; 16(2):327-33. PubMed ID: 18239640
[TBL] [Abstract][Full Text] [Related]
11. Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects.
Madsen EL; Bruun JM; Skogstrand K; Hougaard DM; Christiansen T; Richelsen B
Metabolism; 2009 Jul; 58(7):946-53. PubMed ID: 19409578
[TBL] [Abstract][Full Text] [Related]
12. Compliance, behavior change, and weight loss with orlistat in an over-the-counter setting.
Schwartz SM; Bansal VP; Hale C; Rossi M; Engle JP
Obesity (Silver Spring); 2008 Mar; 16(3):623-9. PubMed ID: 18239553
[TBL] [Abstract][Full Text] [Related]
13. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A
Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
[TBL] [Abstract][Full Text] [Related]
14. What is the long-term efficacy and tolerability of orlistat, a gastrointestinal lipase inhibitor, for the treatment of obesity in primary care?
Leiser JP; Gunning K
J Fam Pract; 2000 Jun; 49(6):572-3. PubMed ID: 10923560
[No Abstract] [Full Text] [Related]
15. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
[TBL] [Abstract][Full Text] [Related]
16. Effect of orlistat in obese patients with binge eating disorder.
Golay A; Laurent-Jaccard A; Habicht F; Gachoud JP; Chabloz M; Kammer A; Schutz Y
Obes Res; 2005 Oct; 13(10):1701-8. PubMed ID: 16286517
[TBL] [Abstract][Full Text] [Related]
17. Orlistat and sibutramine beyond weight loss.
Mannucci E; Dicembrini I; Rotella F; Rotella CM
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
[TBL] [Abstract][Full Text] [Related]
18. An update on the pharmacological treatment of obesity.
Schnee DM; Zaiken K; McCloskey WW
Curr Med Res Opin; 2006 Aug; 22(8):1463-74. PubMed ID: 16870072
[TBL] [Abstract][Full Text] [Related]
19. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss.
Rowe R; Cowx M; Poole C; McEwan P; Morgan C; Walker M
Curr Med Res Opin; 2005 Nov; 21(11):1885-90. PubMed ID: 16307710
[TBL] [Abstract][Full Text] [Related]
20. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss.
Trouillot TE; Pace DG; McKinley C; Cockey L; Zhi J; Häeussler J; Guerciolini R; Showalter R; Everson GT
Am J Gastroenterol; 2001 Jun; 96(6):1888-94. PubMed ID: 11421247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
